Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous administration of higher doses than had been tested in previous studies.

"We found that atacicept was well-tolerated and biologically active at all dose levels in this study, consistent with the results of our other clinical trials," said Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer of ZymoGenetics. "Together with our partner Merck Serono, we will assess the results of this and our other B-cell malignancy studies, once the studies are complete, to see whether the data support moving forward in these indications."

Atacicept in B-CLL Study Design and Results

In a Phase 1b open-label, dose escalation study, 15 patients with refractory or relapsed disease were given weekly intravenous doses of atacicept ranging from 1 mg/kg to 20 mg/kg, for five weeks. Treatment with atacicept was well tolerated at all dose levels in the study. No dose limiting toxicities or serious adverse events related to study drug have been reported to date. Among the six patients given 10 mg/kg and 15 mg/kg, three (50%) showed signs of disease stabilization, using National Cancer Institute-sponsored Working Group criteria, during the treatment period. Prior to atacicept treatment, all of these patients had rapidly increasing leukocyte counts. One patient, who received 10 mg/kg, exhibited stable disease for over six months.

Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, respectively, af
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... the "Global Ophthalmic Diagnostic Devices Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 About Ophthalmic Diagnostic Device ... device used to identify a defect or deficiency in ... patients with ophthalmic disorders such as presbyopia, cataracts, glaucoma, ...
(Date:7/25/2014)... Pa. , July 25, 2014  AMETEK, Inc. ... of Kurtis L. Goos as Vice President ... Materials, Interconnects and Packaging (EMIP) Division. "I ... extensive general management and business development experience, especially in ... make important contributions to the continued growth and success ...
Breaking Medicine Technology:Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... Study Success in Using Virus Enzyme to Treat Mouse ... Be Used to,Prevent Both Ear Infection and Pneumonia in ... -- Parents might one,day give their children a weekly ... them from getting a severe middle ear,infection, based on ...
... the Drug Improves Memory, SARASOTA, Fla., March 22, ... it has received positive,preliminary results in its major ... application for the treatment of Alzheimer's,disease. The clinical ... first human clinical study conducted by a,Florida-based research ...
Cached Medicine Technology:Viral Enzyme Recruited in Fight Against Ear Infection 2Viral Enzyme Recruited in Fight Against Ear Infection 3Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease 2
(Date:7/27/2014)... The North American security and surveillance ... million in 2014, and it is expected to reach ... The report incorporates the factors that influence a country’s ... rates and projected total expenditure. The report also throws ... Apart from the general overview of the companies, it ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The report, ... (Passenger Cars, LCVs & HCVs), Market Type (OE & ... & Diesel) & Geography - Industry Trends & Forecast ... and fuel filters market with analysis and forecasting of ... oil filters is estimated to reach a revenue of ...
(Date:7/27/2014)... 27, 2014 The European Agricultural Adjuvants ... Europe with analysis and forecast of revenue. The agricultural ... around $509.4 million in 2013 to $657.1 million by ... 2018. , Browse through the TOC of the European ... the in-depth analysis provided. It also provides a glimpse ...
(Date:7/27/2014)... 27, 2014 The report provides ... Aviation - Market Analysis (Commercial Aviation And Defense ... Hydraulic, Mechanical) - Forecasts 2014 - 2019." The ... expected to shape the market during the study ... technology trends that are currently prevailing in the ...
(Date:7/27/2014)... 2014 Metachromatic leukodystrophy (MLD, also ... disease which is commonly listed in the family ... as it affects the metabolism of sphingolipids. Leukodystrophies ... fatty covering which acts as an insulator around ... systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, ...
Breaking Medicine News(10 mins):Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... developed a thirst sensor designed to alert the elderly when ... ,The device evaluates the relationship between bodily fat, water ... too little water. ,Four tiny contact strips are ... to a pocketbook-sized apparatus carried next to the body. ...
... might have finally cracked the mystery of the deaths ... Top End.// ,Eye and throat disease had killed ... End's five crocodile farms in recent past weeks. ... suggests the unusually cold dry season and exposure of ...
... are not getting enough sun, and as a result, ... a comeback, experts have revealed in the latest Medical ... rickets are again emerging as major paediatric health issues ... paediatric endocrinologist at the Children’s Hospital at Westmead, Sydney. ...
... ,Egypt is bracing itself for an outbreak of the deadly ... and Sohaj governorates.// ,The first of these cases was ... some 490 kilometers or 305 miles south of Cairo. ... slaughtered and tests are underway to check that none of ...
... women of childbearing age, who would indeed be wise to ... a child with birth defects. // , ,The ... of vitamins and minerals, the risk of many severe birth ... include neural-tube defects such as spina bifida, brain-damaging hydrocephalus, heart ...
... skilled prescribing, warn doctors in this week’s BMJ.Evidence of ... Aronson and colleagues.// Effective treatments are often underprescribed and ... work in hospitals. ,The reasons for ... to system failures, while another fundamental problem is that ...
Cached Medicine News:Health News:More Sunshine for At-Risk Kids 2Health News:Many Medical Students Unprepared for Skilled Prescribing 2
Capable of producing up to 500 volts and 500 milliamps, this power supply is ideal for PAGE, SDS-PAGE, DNA or RNA submarine gels as well as all types of small format transfer apparatus....
... IEF to DNA sequencing, Thermo Series 90 ... routine electrophoretic applications. These power supplies ... or constant power operating modes, with automatic ... power of the Series 90 power supplies, ...
... for horizontal and vertical gel electrophoresis applications. ... In this power supply model, output is ... constant voltage. Four sets of output terminals ... This power supply's light, compact and stackable ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Medicine Products: